Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

This podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant eligibility, frailty, and measurable residual disease assessments. Pharmacists review findings from pivotal trials of daratumumab- and isatuximab-containing regimens, discuss triplet and quadruplet treatment strategies for transplant-eligible and transplant-ineligible patients, and consider the evolving roles of transplantation, maintenance therapy, and response-adapted care. The discussion also addresses pharmacist-led supportive care, toxicity prevention and management, dose modification, and subcutaneous anti-CD38 administration to support individualized treatment selection and safe, sustained therapy.